Article
Eli Lilly promises 40% discount for Innovent's PD-1 in last-ditch bid to shift FDA review to drug pricing
Rating:
0.0
Views:
75
Likes:
1
Library:
1
Eli Lilly has been talking up a “disruptive” pricing strategy for its Innovent Biologics-partnered PD-1 inhibitor Tyvyt in the U.S. | Eli Lilly has been talking up a “disruptive” pricing strategy for its Innovent Biologics-partnered PD-1 inhibitor Tyvyt in the U.S. Now, we have an idea what the company means. But whether it's actually “disruptive?” That's less clear.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value